Fatal systemic toxicity following oral and topical use of Ammi visnaga: A case report - 20/09/25
, Karim Lakhdar d, e, Mohamed Amine El Hasnaoui d, e, Houda Sefiani f, Driss Soussi Tanani a, Hicham Sbai dSummary |
Background |
Ammi visnaga (syn. Visnaga daucoides), widely used in traditional Mediterranean medicine, contains furochromones such as khellin and visnagin known for their vasodilatory, antispasmodic, and photosensitizing properties. While topical applications are more common in ethnomedicine, data on oral toxicity in humans remain limited.
Case presentation |
We report the case of a 21-year-old female with vitiligo who self-administered oral and topical Ammi visnaga powder daily for four months, following recommendations found on social media. She presented with cholestatic jaundice, metabolic acidosis, acute kidney injury, and hepatic dysfunction. Despite intensive care measures, including extracorporeal elimination, N-acetylcysteine, corticosteroids, and vasopressor support the outcome was fatal three days after admission.
Discussion |
The clinical presentation is consistent with the known redox activity of khellin and visnagin, which can induce oxidative stress, mitochondrial dysfunction, and hepatorenal toxicity at high doses. To our knowledge, this is one of the first documented human cases of acute fatal toxicity following oral ingestion of Ammi visnaga. It illustrates the dangers of unsupervised herbal medicine use, particularly when guided by unverified online information.
Conclusion |
This case underscores the need for increased awareness regarding the safe use of medicinal plants and the importance of phytovigilance. It also highlights the potentially severe consequences of self-medication practices based on social media trends.
Le texte complet de cet article est disponible en PDF.Keywords : Ammi visnaga L., Visnaga daucoides L., Khellin, Visnagin, Herbal toxicity, Vitiligo
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
